Login
$TSHA
$4.06 -$0.04 (0.98%) Live

$TSHA SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 8-K: Results of Operations and Financial Condition

REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027

12 Nov 2026 10-Q
14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 SCHEDULE 13G/A
11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6-month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027

10 Jul 2026 Form 4: Nagendran Sukumar, Director

Sold 200,000 shares ($1.25M)

10 Jul 2026 144
25 Jun 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underw...

25 Jun 2026 424B5
24 Jun 2026 424B5
22 Jun 2026 8-K: Regulation FD Disclosure; Other Events

TSHA-102 Rett Syndrome program Update: Longer-term Results from REVEAL Phase 1/2 trials June 2026 Exhibit 99.2

02 Jun 2026 Form 4: Stalfort John A Iii, Director

Received 21,335 shares as a grant or award · Granted 42,671 Stock Option (right to buy)

02 Jun 2026 Form 4: Long Alison S, Director

Received 21,335 shares as a grant or award · Granted 42,671 Stock Option (right to buy)

02 Jun 2026 Form 4: Sepp-Lorenzino Laura, Director

Received 21,335 shares as a grant or award · Granted 42,671 Stock Option (right to buy)

02 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 1, 2026, Taysha Gene Therapies, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders considered four proposals, each of which is described in more detai...

02 Jun 2026 Form 4: Donenberg Phillip B., Director

Received 21,335 shares as a grant or award · Granted 42,671 Stock Option (right to buy)

15 May 2026 SCHEDULE 13G/A
15 May 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support